Dignify Therapeutics to Participate in the BIO Investor Forum, October 2024
The Californer/10293037

Trending...
~ Specialty pharmaceutical company Dignify Therapeutics (Dignify) has been selected as a presenting company at the prestigious BIO Investor Forum in San Francisco. The event, which will take place at the Fairmount Hotel on October 16, 2024, provides a platform for emerging biotech companies to showcase their innovative products and engage with potential investors and partners.

Dignify is dedicated to restoring bowel and bladder function in patients with neurological diseases. Currently, many of these individuals rely on invasive and time-consuming methods such as bladder catheterization and manual bowel programs performed by caregivers. Dignify aims to revolutionize this treatment approach with their two drug programs.

The company's lead drug program, DTI-301, is a suppository that patients can use as needed for bowel evacuation. This medication has shown promising results, inducing defecation within 5-10 minutes with minimal absorption and systemic exposure. Dignify's second drug program, DTI-117, is currently in development for on-demand emptying of both the bladder and bowel. This small peptide directly stimulates smooth muscle contraction in these organs, producing voiding in less than 10 minutes.

More on The Californer
What sets Dignify's drugs apart is their quick action and minimal side effects. DTI-301 has a short plasma half-life and is rapidly eliminated from the body. The development of DTI-117 is also supported by funding from the National Institutes of Health (NIH).

According to Anthony DiTonno, CEO of Dignify Therapeutics, being selected as a presenting company at the BIO Investor Forum is an exciting opportunity for the company. It allows them to showcase their novel approach to treating severe unmet medical needs for patients in a multi-billion dollar market. DiTonno looks forward to engaging with institutional investors and strategic partners at the event as their two drug products approach clinical trials.

Dignify's innovative approach to treating bladder and bowel dysfunction has the potential to greatly improve the quality of life for patients with neurological diseases, diabetes, and the elderly. With their promising drug programs and support from the NIH, Dignify is poised to make a significant impact in this field.
Filed Under: Business

Show All News | Report Violation

0 Comments

Latest on The Californer